Intravenous Ketamine for Treatment-Resistant Depression
Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.
Phase:
PHASE2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Center for Advancing Translational Sciences (NCATS)